Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen: „Eine Lanze für die Parazentese brechen“

Intravitreale Injektionen und akute Nebenwirkungen

Die Parazentese ist ein über Jahrzehnte lang vertrautes Mittel, um einen erhöhten intraokularen Druck (IOD) unmittelbar, kostenarm und nahezu komplikationslos zu eliminieren. Mit der Zulassung von VEGF-Inhibitoren für die Behandlung der altersbedingten Makuladegeneration (AMD) im Jahr 2007 [1] und dem rapiden Anstieg an intravitrealen Injektionen hat die Bedeutung der Parazentese erneute Aufmerksamkeit erlangt. Fakt ist, dass es mit jeder Volumeneingabe in den Glaskörperraum unweigerlich zu einem IOD-Anstieg kommt, der im individuellen Einzelfall beträchtlich sein und zu akuten Sehbeschwerden und Schmerzen führen kann. Eine Parazentese ist in solchen Fällen zwingend erforderlich, um bleibende Schäden zu vermeiden.

• Literatur

• 1 Rosenfeld PJ, Brown DM, Heier JS. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
• 2 Hollands H, Wong J, Bruen R. et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807-811
• 3 Gismondi M, Salati C, Salvetat ML. et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009; 18: 658-661 doi:10.1097/IJG.0b013e31819c4893
• 4 Meyer CH, Rodrigues EB, Aguni J. et al. Scleral incisions evaluated by with anterior segment optical coherence tomography. Am J Ophthalmol 2009; 148: 321 doi:10.1016/j.ajo.2009.04.014
• 5 Rodrigues EB, Grumann jr. A, Penha FM. et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther 2011; 27: 197-203
• 6 Degenring RF, Sauder G. Vitreous prolapse and IOL dislocation during intravitreal injection of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1043-1044
• 7 Viestenz A, Küchle M, Behrens-Baumann W. Bulbusexplosion durch intravitreale Injektion. Klin Monatsbl Augenheilkd 2008; 225: 1087-1090
• 8 Sharei V, Höhn F, Köhler T. et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 2010; 20: 174-179
• 9 Lorenz K, Zwiener I, Mirshahi A. Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1573-1577 doi:10.1007/s00417-010-1490-y
• 10 Ziemssen F, Eter N, Fauser S. et al. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Ophthalmologe 2015; 112: 246-254 doi:10.1007/s00347-014-3217-7
• 11 Munk MR, Ceklic L, Ebneter A. et al. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 2016; 94: e757-e764 doi:10.1111/aos.13157
• 12 Horsley MB, Mandava N, Maycotte MA. et al. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2010; 150: 558-561.e1 doi:10.1016/j.ajo.2010.04.029
• 13 Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2013; 44: 460-464 doi:10.3928/23258160-20130909-07
• 14 Beck M, Munk MR, Ebneter A. et al. Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol 2016; 167: 10-17 doi:10.1016/j.ajo.2016.04.003
• 15 Kopić A, Biuk D, Barać J. et al. Retinal nerve fiber layer thickness in glaucoma patients treated with multiple intravitreal anti-VEGF (bevacizumab) injections. Acta Clin Croat 2017; 56: 406-414 doi:10.20471/acc.2017.56.03.07
• 16 Prager SG, Lammer J, Mitsch C. et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmol 2018; 96: e195-e200 doi:10.1111/aos.13520
• 17 Lanzl I, Kotliar K. [Can Anti-VEGF Injections Cause Glaucoma or Ocular Hypertension?]. Klin Monatsbl Augenheilkd 2017; 234: 191-193 doi:10.1055/s-0043-101819
• 18 Meyer CH, Liu Z, Brinkmann C. et al. Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0-cc syringe. Acta Ophthalmol 2012; 90: e165-e166 doi:10.1111/j.1755-3768.2010.02072.x
• 19 Gerding H, Timmermann M. Accuracy and precision of intravitreally injected ranibizumab doses: an experimental study. Klin Monatsbl Augenheilkd 2010; 227: 269-272
• 20 Kotliar K, Maier M, Bauer S. et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007; 85: 777-781
• 21 Knip MM, Välimäki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 2012; 90: 254-258 doi:10.1111/j.1755-3768.2010.01904.x
• 22 Van der Lelij A, Rothova A. Diagnostic anterior chamber paracentesis in uveitis: a safe procedure?. Br J Ophthalmol 1997; 81: 976-979
• 23 Carnahan MC, Platt LW. Serial paracenteses in the management of acute elevations of intraocular pressure. Ophthalmology 2002; 109: 1604-1606
• 24 Lam DS, Chua JK, Tham CC. et al. Efficacy and safety of immediate anterior chamber paracentesis in the treatment of acute primary angle-closure glaucoma: a pilot study. Ophthalmology 2002; 109: 64-70
• 25 Arnavielle S, Creuzot-Garcher C, Bron AM. Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2007; 245: 345-350
• 26 Cheung CM, Durrani OM, Murray PI. The safety of anterior chamber paracentesis in patients with uveitis. Br J Ophthalmol 2004; 88: 582-583
• 27 Trivedi D, Denniston AK, Murray PI. Safety profile of anterior chamber paracentesis performed at the slit lamp. Clin Exp Ophthalmol 2011; 39: 725-728 doi:10.1111/j.1442-9071.2011.02565.x
• 28 Kitazawa K, Sotozono C, Koizumi N. et al. Safety of anterior chamber paracentesis using a 30-gauge needle integrated with a specially designed disposable pipette. Br J Ophthalmol 2017; 101: 548-550 doi:10.1136/bjophthalmol-2016-309650
• 29 Azuara-Blanco A, Katz LJ. Infectious keratitis in a paracentesis tract. Ophthalmic Surg Lasers 1997; 28: 332-333
• 30 Helbig H, Noske W, Kleineidam M. et al. Bacterial endophthalmitis after anterior chamber paracentesis. Br J Ophthalmol 1995; 79: 866
• 31 Meyer CH, Rodrigues EB, Michels S. et al. Incidence of damage to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 2010; 26: 491-495 doi:10.1089/jop.2010.0045
• 32 Xing L, Dorrepaal SJ, Gale J. Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can J Ophthalmol 2014; 49: 261-266
• 33 Funk M, Karl D, Georgopoulos M. et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009; 116: 2393-2399 doi:10.1016/j.ophtha.2009.05.039
• 34 Muether PS, Hermann MM, Dröge K. et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 2013; 156: 989-993.e2 doi:10.1016/j.ajo.2013.06.020
• 35 dellʼOmo R, Cassetta M, dellʼOmo E. et al. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study. Am J Ophthalmol 2012; 153: 155-161.e2
• 36 Rezar-Dreindl S, Eibenberger K, Pollreisz A. et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol 2017; 95: e119-e127 doi:10.1111/aos.13152
• 37 Garweg JG, Zandi S, Pfister IB. et al. Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma. PLoS One 2017; 12: e0182571
• 38 Ichiyama Y, Sawada T, Kakinoki M. et al. Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration. Ophthalmic Res 2014; 52: 234-238 doi:10.1159/000365253
• 39 Bach A, Filipowicz A, Gold AS. et al. Paracentesis following intravitreal drug injections in maintaining physiologic ocular perfusion pressure. Int J Ophthalmol 2017; 10: 1925-1927 doi:10.18240/ijo.2017.12.22
• 40 Soheilian M, Karimi S, Montahae T. et al. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefes Arch Clin Exp Ophthalmol 2017; 255: 1705-1712 doi:10.1007/s00417-017-3702-1
• 41 Enders P, Sitnilska V, Altay L. et al. Retinal nerve fiber loss in anti-VEGF therapy for age-related macular degeneration can be decreased by anterior chamber paracentesis. Ophthalmologica 2017; 237: 111-118 doi:10.1159/000457907